Premium
Recurrence of hodgkin's disease after indium‐111 and yttrium‐90 labeled antiferritin administration
Author(s) -
Vriesendorp Huibert M.,
Quadri Syed M.,
Andersson Borje S.,
Wyllie Cynthia T.,
Dicke Karel A.
Publication year - 1997
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/(sici)1097-0142(19971215)80:12+<2721::aid-cncr51>3.0.co;2-a
Subject(s) - radiation therapy , nuclear medicine , medicine , surgery
BACKGROUND Indium‐111 labeled antiferritin targets 95% of all Hodgkin's disease lesions with a diameter of 1 cm or more. Subsequent treatment with yttrium‐90 labeled antiferritin secures a high response rate in patients with recurrent Hodgkin's disease. METHODS A total of 87 patients were entered on one of three different yttrium‐90 labeled antiferritin protocols. Recurrences after yttrium‐90 treatment were analyzed. Nine patients were retreated with involved external beam radiation fields, selected with the help of indium‐111 labeled antiferritin. RESULTS In single‐agent yttrium‐90 antiferritin studies, a response rate of more than 60% was found, with an average response duration of 6 months. One‐third of the patients had recurrences in previously uninvolved areas. Repeat indium antiferritin scintigraphy allowed for the selection of new radiation fields for recurrences. In‐field disease control was obtained for a median of 8 months, but new recurrences in new areas occurred. Chemotherapy or radiation therapy given immediately before antiferritin decreased tumor targeting with indium‐111 labeled antiferritin. CONCLUSIONS Recurrences after radiolabeled antiferritin treatment are not due to radioresistant Hodgkin's disease. In contrast, Hodgkin's disease less than 1 cm in diameter is not targeted and not controlled by radiolabeled antiferritin. New multimodality regimens with a higher therapeutic ratio are needed for treatment of Hodgkin's disease with curative intent. Radiolabeled antiferritin can be incorporated in such regimens to secure better control of bulky Hodgkin's disease (>1 cm in diameter), but it should be given before chemotherapy or radiation therapy. Cancer 1997; 80:2721‐7. © 1997 American Cancer Society.